Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Adamax is a synthetic 9-amino-acid research peptide representing the most heavily modified member of the Semax family, engineered specifically to address Semax's pharmacokinetic limitations through two distinct stabilizing modifications. The compound is sometimes described as "N-Acetyl-Semax with C-terminal adamantane", capturing both modifications in the name. Adamax represents an unusual case in the library because it combines two sophisticated peptide modification strategies: the Russian Semax/Selank PGP-extension tradition (extending ACTH(4-7) with Pro-Gly-Pro) plus the adamantane stabilization approach (the same C-terminal modification used in P21, the CNTF mimetic).
The full Adamax structure includes the base Semax sequence (Met-Glu-His-Phe-Pro-Gly-Pro), ACTH(4-7) with PGP extension, plus N-terminal acetylation protecting against aminopeptidases, and a C-terminal adamantylacetate group through covalent bonding. This dual-modification approach achieves dramatically improved pharmacokinetics compared to native Semax: half-life extended to several hours (vs ~30-60 min for Semax), enhanced BBB penetration from the lipophilic adamantane, near-complete enzymatic resistance, significantly improved temperature stability, and a duration of action measured in hours rather than minutes. Adamax represents the most clinically obscure compound in the library, substantially less researched than Semax, less commercially available than P21, and with the smallest user base of any compound covered. It is genuinely a research compound used in Russian cognitive-peptide studies and by advanced biohackers exploring ACTH-derived peptides, rather than a mainstream nootropic.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Intranasal Adamax | Several hours |
| Subcutaneous Adamax | Several hours |
| Oral Adamax | Limited / not standard |
What it does
Main effects
- BDNF upregulation in hippocampus: Primary mechanism (same as Semax but sustained); enhanced CNS delivery via adamantane modification means more efficient and longer-lasting BDNF elevation
- TrkB receptor sensitization: Modestly stronger than Semax due to pharmacokinetic improvements; drives neuronal survival, synaptic plasticity, memory consolidation, mood regulation, neurogenesis, and neuroprotection
- NGF (nerve growth factor) upregulation: Effects on cholinergic neurons in basal forebrain; memory-related cholinergic function; neuroprotection; cognitive enhancement
- Dopaminergic, serotonergic, and cholinergic modulation: Similar to Semax; contributes to attention, motivation, executive function, mood effects, and memory enhancement
- NO hormonal ACTH activity: Preserved from Semax design; no cortisol elevation, no adrenal cortex stimulation, no HPA axis disruption; ACTH 4-7 truncation strategy maintained
- Anti-inflammatory CNS effects: Suppression of neuroinflammatory cascades; modulation of immune response genes; neuroprotection
- Possible MC4R activation: Some sources suggest melanocortin 4 receptor involvement; contributes to cognitive effects; less established than BDNF mechanism
- Extended duration of action: Longer half-life sustains exposure over hours rather than the short window seen with Semax; plasma levels are correspondingly more stable
- Enhanced BBB penetration: Lipophilic adamantane modification; better blood-brain barrier crossing than native Semax; wider distribution likely due to lipophilicity
What to watch for
Common side effects
- Sleep disturbance: Adamax-specific concern given longer half-life; the extended duration means an evening dose overlaps sleep more than Semax does
- Nasal irritation: From intranasal administration; generally mild; follows Semax family pattern
- Mild headache: Occasional reports from non-medical use
- Vivid dreams: Some users report; related to longer half-life and CNS activity
- Mild stimulation: Reported more often when the dose falls late in the day; tracks the extended duration of action
- Limited safety data: Small research base means rare adverse events are unknown; long-term effects uncharacterized; special populations not studied
- Product identity and purity: Adamax requires specialized adamantane synthesis and multiple structural variants appear in the literature, so material sold under the name is not reliably one defined compound; identity is difficult to establish without mass spectrometry
- Not WADA-prohibited as of current information (verify before use in tested sport). Status uncertain given obscurity
Key facts
Key facts worth knowing
- Adamax is a synthetic 9-amino-acid research peptide with structure Ac-Met-Glu-His-Phe-Pro-Gly-Pro-AG-NH₂ (some sources note slight variations). Built from Semax (7 aa) plus two C-terminal amino acids plus N-acetylation plus adamantyl modification. Molecular weight approximately 1100-1200 Da depending on exact form.
- Naming origin: "ADAMAX" combines "ADAMA" (from adamantane) + "X" (suggesting next-generation Semax). The compound is sometimes called N-Acetyl-Semax-Amidate or N-Acetyl-Semax-Adamantyl depending on source.
- Developed within the Russian neuropeptide research tradition at the Institute of Molecular Genetics of the Russian Academy of Sciences (same institute that produced Selank and Semax). The Russian research team applied the adamantane stabilization strategy (used in various pharmaceutical contexts) to Semax to address its main pharmacokinetic limitations.
- The adamantane group provides multiple benefits: enhanced absorption through lipid membranes; increased lipid solubility for blood-brain barrier penetration; resistance to exopeptidase degradation; temperature stability (vs amidation alone); extended half-life to several hours vs Semax's 30-60 minutes.
- Same adamantane strategy as P21: Both compounds use the adamantyl modification for blood-brain barrier penetration and metabolic stability. Adamax: Semax-based; targets ACTH 4-7 effects (BDNF, NGF, TrkB). P21: CNTF-mimetic; targets CNTF-like effects via LIF pathway inhibition. Iqbal K, Kazim SF, Bolognin S, Blanchard J. Shifting Balance from Neurodegeneration to Regeneration of the Brain. Neural Regeneration Research 2014. PMC: 4192968 [Context for adamantane modification approach]
- No regulatory approval anywhere: not approved by FDA, EMA, MHRA, Russian Pharmaceutical Authority (despite the Russian development origin), or any other major regulator. NOT included in the FDA PCAC review that is evaluating Semax.
- Evidence comparison with Semax: Adamax has substantially less evidence than Semax (30+ years Russian clinical use, ongoing FDA PCAC review, Russian/Ukrainian regulatory approval). Adamax is the same pharmacology with better delivery, but Semax has far better evidence validation.
Legal status
Legal status
No regulatory approval anywhere. Sold strictly as a research compound. Significantly more obscure than Semax in distribution. Not specifically WADA prohibited (verify before use in tested sport). Not on FDA bulk drug substance lists for compounding. Not scheduled as controlled substance in the United States.